Compare GDS & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDS | CYTK |
|---|---|---|
| Founded | 2001 | 1997 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 8.0B |
| IPO Year | 2016 | 2004 |
| Metric | GDS | CYTK |
|---|---|---|
| Price | $34.44 | $60.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 15 |
| Target Price | $46.20 | ★ $77.87 |
| AVG Volume (30 Days) | 1.7M | ★ 1.8M |
| Earning Date | 11-19-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 3.59 | N/A |
| Revenue | ★ $1,573,383,809.00 | $87,211,000.00 |
| Revenue This Year | $13.10 | $361.33 |
| Revenue Next Year | $12.55 | $65.14 |
| P/E Ratio | $42.29 | ★ N/A |
| Revenue Growth | 11.86 | ★ 2609.26 |
| 52 Week Low | $16.93 | $29.31 |
| 52 Week High | $52.50 | $69.33 |
| Indicator | GDS | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 50.61 | 44.45 |
| Support Level | $34.97 | $59.56 |
| Resistance Level | $36.96 | $64.12 |
| Average True Range (ATR) | 1.04 | 2.42 |
| MACD | 0.21 | -0.73 |
| Stochastic Oscillator | 35.83 | 13.10 |
GDS Holdings started as an IT service provider in 2001 then moved to the data center business with its first self-developed data center opening in 2010. The company now develops and operates data centers in China and also builds, operates and transfers data centers for other clients. It offers colocation and managed services and mainly targets hyperscale cloud service customers who take large areas of its data centers or even whole data centers under long-term contracts. Its data centers are located predominantly in and around the Tier 1 cities in China and it has also started an expanding into Southeast Asia via the now 38% owned DayOne. GDS listed on the Nasdaq in 2016 and completed a secondary listing in Hong Kong in 2020.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.